We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Horizon Therapeutics Public Limited Company | NASDAQ:HZNP | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 116.30 | 116.31 | 116.30 | 0 | 01:00:00 |
From May 2022 to May 2024
14:26 ET -- Amgen is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The U.S. Federal Trade Commission filed a lawsuit in federal court seeking an injunction that would prevent Amgen's $27.8 billion acquisition of Horizon Therapeutics from closing. The FTC said the deal would allow Amgen to "entrench the monopoly positions" of Horizon's eye and gout drugs. Amgen said it is disappointed in the FTC's decision, but doesn't believe a merger presents competitive issues and will still work to close the deal by mid-December. (jennifer.tershak@wsj.com)
(END) Dow Jones Newswires
May 16, 2023 14:43 ET (18:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Horizon Therapeutics Pub... Chart |
1 Month Horizon Therapeutics Pub... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
